Alterity Therapeutics Future Growth

Alterity Therapeutics's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 25% per year.

-2.7%

Earnings growth rate

n/a

EPS growth rate

No updates

Earnings and Revenue Growth Forecasts

BST:PBN0 - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	7	-20	N/A	-20	1
6/30/2025	9	-18	-8	-18	1
6/30/2024	4	-19	-13	-13	N/A
3/31/2024	4	-16	-14	-14	N/A
12/31/2023	3	-12	-15	-15	N/A
9/30/2023	4	-13	-17	-17	N/A
6/30/2023	4	-14	-20	-20	N/A
3/31/2023	5	-14	-17	-17	N/A
12/31/2022	5	-14	-14	-14	N/A
9/30/2022	5	-14	-13	-13	N/A
6/30/2022	5	-13	-12	-12	N/A
3/31/2022	5	-13	-16	-16	N/A
12/31/2021	5	-13	-19	-19	N/A
9/30/2021	5	-14	-18	-18	N/A
6/30/2021	4	-15	-17	-17	N/A
3/31/2021	2	-16	-16	-16	N/A
12/31/2020	0	-16	-14	-14	N/A
9/30/2020	0	-15	-12	-12	N/A
6/30/2020	N/A	-13	-9	-9	N/A
3/31/2020	2	-13	-9	-9	N/A
12/31/2019	4	-13	-9	-9	N/A
9/30/2019	5	-12	-12	-12	N/A
6/30/2019	5	-12	-14	-14	N/A
3/31/2019	5	-11	-13	-13	N/A
12/31/2018	4	-10	-12	-12	N/A
9/30/2018	4	-9	-9	-9	N/A
6/30/2018	3	-8	-6	-6	N/A
3/31/2018	3	-8	N/A	-6	N/A
12/31/2017	3	-8	N/A	-6	N/A
9/30/2017	3	-8	N/A	-6	N/A
6/30/2017	3	-8	N/A	-6	N/A
3/31/2017	4	-8	N/A	-3	N/A
12/31/2016	4	-9	N/A	-1	N/A
9/30/2016	4	-8	N/A	-4	N/A
6/30/2016	5	-8	N/A	-7	N/A
3/31/2016	5	-8	N/A	-9	N/A
12/31/2015	6	-7	N/A	-10	N/A
9/30/2015	6	-7	N/A	-10	N/A
6/30/2015	6	-6	N/A	-11	N/A
3/31/2015	8	-6	N/A	-13	N/A
12/31/2014	10	-7	N/A	-15	N/A
9/30/2014	9	-10	N/A	-14	N/A
6/30/2014	8	-13	N/A	-14	N/A
3/31/2014	6	-12	N/A	-12	N/A
12/31/2013	4	-11	N/A	-11	N/A

Earnings vs Savings Rate: PBN0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PBN0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PBN0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PBN0's revenue (25% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: PBN0's revenue (25% per year) is forecast to grow faster than 20% per year.

Future ROE: Insufficient data to determine if PBN0's Return on Equity is forecast to be high in 3 years time